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Abstract
Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy
for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely
unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20,
Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also
associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production
during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results
indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.
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Introduction
Multiple Sclerosis (MS) is an immune-mediated demyelinating
disease of the central nervous system (CNS) and an important
cause of disability in young adults [1]. The involvement of the
immune system in MS is supported by the effectiveness of current
anti-inflammatory therapies to reduce clinical symptoms and slow
progression of disability [1,2]. One potential therapy is Rituximab
(HRituxan), which is a humanized mouse monoclonal antibody
(mAb) against the human CD20 surface molecule expressed by B
cells [3]. Initial case reports indicate that Rituximab therapy was
beneficial for MS patients [4]. A phase II double-blind placebo-
controlled trial showed a significant reduction of gadolinium
enhancing lesions at 4 weeks post-therapy and relapses at 12 weeks
post-Rituximab therapy that were maintained for the 48 week
duration of the trial [5]. The mechanisms through which
Rituximab exerts its effects remain incompletely understood.
This study was designed to investigate the impact of B cell
depletion on the T cell response during EAE. It is based on a
transgenic mouse that expresses human CD20 (hCD20) under its
own hCD20 promoter [6]. Using the MOG1–125-induced model of
experimental autoimmune encephalomyelitis (EAE), we demon-
strate that EAE severity is dramatically reduced in hCD20Tg mice
treated with Rituximab prior to immunization or at the onset of
clinical signs. Rituximab depletes B cells in the peripheral blood,
secondary lymphoid organs and CNS. The absence of disease
progression was associated with changes in the CNS-associated
CD4 T cell compartment including a decline in MOG-specific T
cell proliferative responses and a specific decrease in IL-17
production.
Materials and Methods
Mice
hCD20Tg mice were described previously [6]. The hCD20Tg
and littermate control mice were backcrossed to the C57.BL/6
(B6) genetic background for .12 generations for these studies.
Animal protocols were approved by the Institutional Animal Care
and Research Advisory Committee.
EAE induction and DTH responses
EAE was induced by subcutaneous immunization with 200 mg
of recombinant human MOG1–125 emulsified in complete
Freund’s adjuvant (CFA) containing 5 mg/ml of mycobacteria
(Difco). On days 0 and 2, each mouse received 200 ng pertussis
toxin (Toxin Technologies). EAE severity was scored following a
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elicited by injection of MOG1–125 in the ear pinna and net swelling
determined at 24 hours as previously described [7].
Antibodies and recombinant proteins
Rituximab (Genentech) was administered at 100 mg/mouse
daily for 3 days. Fluorophore-conjugated antibodies against
murine CD4, CD8, CD19, CD45, CD45R and TCRb or human
CD20 were acquired from BD Biosciences or eBioscience.
MOG1–125 was generated as previously described [9]. MHC class
II tetramers containing hCLIP103–117 or MOG38–48 were obtained
from the NIH tetramer core facility.
Cell culture
T cell proliferation was determined by CFSE dilution after 6
days of in vitro stimulation. IFNc and IL-17 levels were
determined from 48-hour culture supernatants by ELISA
(eBioscience).
Flow cytometry
Single cell suspensions of spleen and CNS tissues were acquired
by mechanical disruption through 70 mM mesh. CNS samples
were further centrifuged through a 70:30 discontinuous percoll
gradient. Nonspecific binding was blocked with Fc receptor
blocking agents and stained with fluorophore conjugated mAbs as
previously described [10].
Statistical Analyses
Where indicated, statistical comparisons were performed using
GraphPad Prism5 software. Correlations between continuous and
categorical variables were assessed using the Mann-Whitney U
test. The means of two normally distributed samples were
compared by Student t-test. All other statistical comparisons
between groups were examined using one-way multiple range
ANOVA test for multiple comparison. P-values ,0.05 were
considered significant.
Results
EAE severity is similar in hCD20Tg and WTLM mice
The frequency of T and B cells in mice expressing the hCD20
transgene (hCD20Tg) was found to be similar to littermate
controls (WTLM), as described previously [6]. In addition,
susceptibility to MOG1–125 induced EAE was similar in hCD20Tg
and WTLM mice (Figure 1A). The onset of disease was found to
be on day 8 post-immunization with peak disease on day 12 for
both groups. The WTLM and hCD20Tg mice could not be
distinguished statistically in terms of peak severity (WTLM 4.0 vs
hCD20Tg 3.7) or mean cumulative disease score (WTLM 16.1 vs.
hCD20Tg 13.5). Thus, the expression of human CD20 by B cells
does not significantly alter the immune response leading to EAE.
Rituximab treatment alters EAE severity
To understand the impact of B cell depletion on EAE induction,
hCD20Tg and WTLM mice were treated with Rituximab for 3
days prior to induction of EAE using recombinant human
MOG1–125 as described in materials and methods. One group of
untreated WTLM is included as a control. Moderate to severe
EAE was observed in both untreated and Rituximab-treated
WTLM mice (Figure 1B), while hCD20Tg mice were protected
from developing EAE. Rituximab-treated hCD20Tg mice showed
a significant reduction in serum anti-MOG IgG titers (p,0.02)
(Figure 1C), and frequency of peripheral B cells (p,0.01)
(Figure 1D). B cells, CD4 and CD8 T cell numbers were reduced
in the spleen of hCD20Tg mice even three weeks after the last
treatment with Rituximab (Table 1). B cells and CD4 T cells were
also reduced in the CNS of hCD20Tg mice 3 weeks after the last
treatment with Rituximab. In contrast, CD8+ T cell frequencies
were increased in the spleens and CNS three weeks after the last
treatment with Rituximab. Minor variance between groups was
observed with regard to B and T cell frequencies in WTLM mice
either treated or untreated with Rituximab (data not shown).
Next, the effects of B cell depletion on active disease was
examined by treating hCD20Tg and WTLM mice with
Rituximab for three days beginning on the day after EAE disease
onset. Rituximab treatment rapidly decreased EAE severity in the
hCD20Tg, but not WTLM mice (Figure 1E). This short course of
treatment resulted in a sharp reduction in B cells within the
peripheral blood (Figure 1F), spleen and CNS (Table 2).
Rituximab therapy also showed significant effects on T cell
numbers in the spleen (Table 2).
Rituximab treatment reduces inflammatory T cell
responses
To determine if Rituximab is acting directly on T cells,
experiments were performed to examine the expression of hCD20
on B and T cells. As has been described [6], hCD20 was readily
detected on splenic (Figure 2A) and LN B cells (data not shown)
from hCD20Tg but not WTLM mice. Next, the effects of
Rituximab treatment were examined on B cell populations in vivo.
B cells were rapidly and significantly depleted in the peripheral
blood of hCD20Tg mice following administration of Rituximab
(Figure 2B) as well as other anti-human CD20 mAbs including 1F5
(data not shown) [11–13]. Three daily doses of Rituximab
routinely resulted in rapid (within 96 hours) and near complete
depletion of B cells in the peripheral blood. Rituximab treatment
also caused a significant, albeit incomplete, depletion of B cells
within the SPL (Figure 2C) and LN (Figure 2D) of hCD20Tg
mice.
Because our understanding of EAE pathogenesis is largely based
on the function of autoreactive T cells, the T cell pool of
hCD20Tg mice was also carefully examined. CD4 and CD8 T cell
frequencies, as well as activated or memory T cell frequencies in
the thymus, SPL and LN were similar in hCD20Tg and WTLM
mice (data not shown). The expression of human CD20 was not
detected on splenic T cells (Figure 2E), LN (data not shown) or
thymus (data not shown) of WTLM or hCD20Tg mice. Splenic
(Figure 2F) and lymph node (Figure 2G) CD4 T cells were reduced
following Rituximab treatment. The decrease in T cell frequency
following Rituximab treatment is likely a consequence of B cell
depletion rather than a direct effect of Rituximab on T cells, as
previously suggested in Rituximab-treated patients [14,15].
Rituximab treatment alters immune responses
In order to better ascertain the effects of Rituximab adminis-
tration on anti-MOG T cell responses, in vivo and in vitro
functional assays were performed. hCD20Tg and WTLM mice
were treated with Rituximab prior to EAE induction. MOG-
specific delayed type hypersensitivity (DTH) assays were per-
formed 10 days post-EAE induction as an in vivo measurement of
peripheral T cell priming potential. Rituximab treatment prior to
immunization did not prevent the generation of effective DTH
responses to MOG1–125 induced EAE (Figure 2H), and MOG-
specific T cell numbers were similar in the WTLM and hCD20Tg
mice (Figure 3A and 3B). However, MOG-specific T cell recall
responses and IL-17 levels were reduced in Rituximab-treated
hCD20Tg mice (Figure 3C, 3D). rMOG or anti-CD3-elicited
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mice (Figure 3E) or WTLM mice. These results support a role for
B cells in promoting MOG-specific Th17 responses in vivo.
Discussion
Recent results of clinical trials using Rituximab have led to the
re-examination of the function of B cells in MS pathogenesis. Here
we have described a role for B cells in EAE pathogenesis using the
MOG1–125-induced model of disease, in which Rituximab
administration suppressed EAE severity when given prior to
immunization EAE induction or at disease onset.
The effects of Rituximab treatment on EAE were associated
with: altered CD4+ T cell distribution in the blood, spleen and
lymph nodes; altered T cell recall proliferation; and diminished
antigen-elicited production of IL-17. Interestingly, the number of
MOG-specific T cells identified by tetramer staining was similar in
non-transgenic littermate mice and hCD20Tg mice that were
treated with Rituximab at the time of EAE elicitation (Figure 3),
although T cell proliferation and IL-17 secretion in response to
MOG1–125 was decreased in the hCD20Tg mice compared to
non-transgenic littermate mice. In fact, Rituximab treatment failed
to suppress MOG-specific DTH responses indicating that B cell
depletion did not prevent the priming of an autoimmune T cell
response. We therefore conclude that the major effects of
Rituximab in this model are not due to a direct depletion of
MOG-specific T cells during the priming or effector phase but
rather point to B cells being critical for the induction or
maintenance of neuroinflammation. These results also support
the conclusion that Rituximab may function in a tissue dependent
manner, and that it does not cause generalized immune
suppression [16]. Clinical observations on the organ-specific
adverse events associated with Rituximab support our findings
[17].
Figure 1. Disruption of EAE pathogenesis by B cell depletion. Panel A. EAE severity is similar in WTLM and hCD20Tg mice. EAE onset and
severity were monitored using a 5-point scale on WTLM and hCD20Tg mice immunized with MOG1–125. These results are representative of at least
two independent experiments. Panels B–D. Rituximab administration prevents the induction of EAE. WTLM or hCD20Tg mice were either left
untreated or were injected with 100 mg Rituximab daily for three days (Day -3,-2,-1). On Day 0, EAE was induced by immunization with MOG1–125.
Panel B. Disease course of WTLM and hCD20Tg mice, EAE onset and severity was monitored using a 5-point scale. Shown are the mean clinical score
+/2 SEM. Panel C. B cell depletion results in reduced levels of anti-MOG IgG in the serum. Serum was harvested on day 21 post-immunization and
MOG-specific IgG levels were determined by ELISA. Results shown are the mean IgG concentration +/2 SEM. Asterix indicates significant decrease as
compared to Rituximab-treated WTLM mice. Panel D. Rituximab administration results in rapid depletion of B cells in the peripheral blood. Blood
was taken from WTLM or hCD20Tg mice 3 days following the final dose of Rituximab (day 2 post-immunization). B cells were identified by flow
cytometry using gates to identify lymphocytes and CD19 expressing cells. Results shown are the mean percentages of CD19+ B cells +/2SEM
(*, p,0.01). Panels E/F. Treatment with Rituximab reduces EAE severity. EAE was initiated in WTLM and hCD20Tg mice on Day 0. Upon the
appearance of clinical signs of EAE, Rituximab (100 mg) was administered daily for three treatments. Panel E. Disease course of WTLM and hCD20Tg
mice, EAE onset and severity was monitored using a 5-point scale. Shown are the mean clinical score +/2 SEM. Panel F. B cell depletion in peripheral
blood on day 20. Significant differences were determined using an unpaired t-test (*, p,0.05; **, p,0.01). These results are representative of at least
two independent experiments with Rituximab and two experiments using the 1F5 anti-human CD20 mAb (data not shown).
doi:10.1371/journal.pone.0017103.g001
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Rituximab administration.
Splenocytes CNS
WTLM hCD20Tg WTLM hCD20Tg
Total cells 1.21610
8 7.60610
7
(37.2%)
1.50610
5 2.00610
5
(233.3%)
B cells 3.21610
7 1.18610
7
(63.2%)
2.20610
3 1.91610
3
(13.2%)
CD4+ T cells 2.13610
7 1.44610
7
(32.4%)
3.54610
4 1.05610
4
(70.34%)
CD8+ T cells 1.02610
7 7.12610
6
(30.2%)
1.41610
4 3.92610
4
(2178.0%)
Cells from each organ were pooled from at least three mice per group and
counted. Cell counts were then normalized by dividing the total counts by the
numbers of mice in each group and then multiplied by the percentage of each
cell type as identified by flow cytometry. Total leukocytes were identified by
CD45+ events within FSC and SSC gates. B cells were identified using gates for
CD19 and B220. T cells were identified by expression of CD3 and either CD4 or
CD8. Numbers in parenthesis indicate the percent change in cell counts in the
hCD20Tg mice as compared to WTLM controls.
doi:10.1371/journal.pone.0017103.t001
Table 2. B and T cell frequency in therapeutic model of
Rituximab administration.
Splenocytes CNS
WTLM hCD20Tg WTLM hCD20Tg
Total cells 1.15610
8 6.28610
7
(45.4%)
1.67610
5 1.23610
5
(26.3%)
B cells 4.72610
7 1.05610
7
(77.8%)
2.08610
4 3.22610
3
(84.5%)
CD4+ T cells 2.01610
7 1.47610
7
(27.1%)
2.39610
4 1.57610
4
(34.6%)
CD8+ T cells 9.35610
6 6.81610
6
(27.2%)
7.29610
3 5.34mt10
3
(26.7%)
Cells from each organ were pooled from at least three mice per group and
counted. Cell counts were then normalized by dividing the total counts by the
numbers of mice in each group and then multiplied by the percentage of each
cell type as identified by flow cytometry. Total leukocytes were identified by
CD45+ events within FSC and SSC gates. B cells were identified using gates for
CD19 and B220. T cells were identified by expression of CD3 and either CD4 or
CD8. Numbers in parenthesis indicate the percent change in cell counts in the
hCD20Tg mice as compared to WTLM controls.
doi:10.1371/journal.pone.0017103.t002
Figure 2. B and T cell dynamics following Rituximab treatment. Panels A and E. Expression of human CD20 by hCD20Tg B cells and
hCD20Tg T cells. Splenocytes from WTLM and hCD20Tg mice were stained with antibodies to human CD20, CD4 and CD19 and flow cytometry
performed. Results shown are gated on CD19+CD42 events to identify B cells or gated on CD192CD4+ events to identify T cells. Panels B/C/D/F/G.
WTLM and hCD20Tg mice received three daily injections of Rituximab (100 mg) beginning on day 0. At 144 hours after Rituximab treatment was
initiated, tissues were harvested for flow cytometry analysis. Panel B. Peripheral B cells are rapidly depleted following Rituximab treatment. Panel C.
Splenic B cells are depleted following Rituximab treatment. Panel D. B cells in the LN (Axilary, Brachial and Inguinal) are depleted following
Rituximab treatment. Panel E. CD4 T cells do not express human CD20. Panel F. Splenic CD4 T cells are reduced following Rituximab treatment.
Panel G. CD4 T cells in the LN (Axilary, Brachial and Inguinal) are reduced following Rituximab treatment. Panel H. Rituximab administration does
not prevent priming of inflammatory T-effector cells. WTLM and hCD20Tg mice were treated with Rituximab daily for 3 days (Day -3,-2,-1), followed by
immunization with MOG1–125 on Day 0. On day 10 post-immunization, DTH responses were elicited by subcutaneous injection of MOG1–125 (10 mg) in
the ear. The net ear swelling responses were determined at 24 hours. Results shown indicate the mean ear swelling in mmX10E-3 (background
subtracted) +/2 SEM. Significant differences were detected by unpaired t-test (*, p,0.05; **, p,0.01). These results are representative of at least two
independent experiments.
doi:10.1371/journal.pone.0017103.g002
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17103Figure 3. Rituximab administration alters MOG-specific recall responses. Panels A–E. WTLM and hCD20Tg mice were treated with
Rituximab daily for 3 days (Day -3,-2,-1) followed by immunization with MOG1–125 on Day 0. On day 20 post-immunization, bulk draining lymph node
cells (LNC) were isolated and recall response determined. Panels A and B. Identification of MOG-reactive T cells by tetramer staining. Bulk LNC were
cultured for 3 days in the presence of MOG1–125 prior to labeling with antibodies to CD3, CD4 and I-Ab tetramers to either human (A) CLIP103–117 or (B)
MOG38–48. Numbers above boxes indicate percentages of T cells in the tetramer positive gate. Panel C. Secondary T cell proliferative responses were
determined by CFSE dilution assay. LNC were labeled with CFSE and placed in culture with 20 mg/ml MOG1–125 and proliferation determined by flow
cytometry on day 6 of culture. Results shown are gated on CD4+ events. Numbers indicate the percentage of total cells that diluted CFSE from WTLM
and hCD20Tg mice. Panels D and E. 48-hour supernatants from the Panel C experiments were examined for the presence of IL-17 (D) or IFNc (E) by
ELISA. Asterices indicate a significant decrease in IL-17 production (p,0.05). Results are representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0017103.g003
Role of B Cells in EAE
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17103A subset of B cells has been identified in mouse models that can
reduce inflammation by producing immunomodulatory cytokines
such as IL-10 [18]. Others have further detailed that in peptide-
induced EAE models, IL-10 producing B cells could promote
remission of EAE [19,20]. However, our results support a role for
B cells in promoting CNS inflammation at the level of maintaining
T cell proliferation and Th17 differentiation when EAE is induced
with MOG1–125. Indeed, a recent publication by Weber et al
demonstrates that B cells from MOG1–125 induced EAE mice
activate encephalitogenic T cells in vitro more effectively than B
cells from MOG35–55 induced EAE mice [21], and antigen
experienced B cells from RRMS patients also induce inflammatory
responses by CD4 T cells in a neuro-antigen specific manner [22].
The anti-inflammatory effects of Rituximab may be mediated
through the role of B cells as antigen specific APCs to
encephalitogenic T cells [22], perhaps through their secretion of
IL-6 [23].
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